BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 27795437)

  • 1. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
    Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Chong H; Zhu Y; Yu D; He Y
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
    Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
    J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Qiu Z; Xiong S; He Y
    J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y; Ding X; Yu D; Chong H; He Y
    J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L; Gochin M; Liu K
    Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
    Chong H; Qiu Z; Su Y; Yang L; He Y
    AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
    Champagne K; Shishido A; Root MJ
    J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
    J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
    Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
    Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
    Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
    J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E; Hummer G; Bewley CA; Clore GM
    J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
    Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.